{"component": "clause", "props": {"groups": [{"size": 24, "snippet": "(a) Not later than three [***] after submission of Regulatory Filings for each Product in each country of the Territory, Licensee will provide to the JCC for review its initial Commercialization Plan for each Product for each country in the Territory. Such initial Commercialization Plan will describe Licensee\u2019s plans for activities to be conducted for such Product for such country. Each Commercialization Plan shall include the details of obligations to be performed by Licensee to achieve the specific activities that are applicable to the stage of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization (e.g., pre-launch, launch planning, launch, or post-launch) of the applicable Product during the time period covered by such Commercialization Plan and subsequent time periods.\n(b) Prior to the First Commercial Sale for such Product in such country, Licensee will provide to the JCC for review an updated Commercialization Plan for such Product for such country. Such updated Commercialization Plan will include, but not be limited to, Licensee\u2019s updated plans for activities to be conducted for such Product for such country prior to launch as well as activities to be conducted in connection with such launch.\n(c) Promptly after each anniversary of the First Commercial Sale of such Product during the Term, Licensee will provide to the JCC for review updated Commercialization Plans for such Product for such country. Such further updated Commercialization Plan will include, but not be limited to, Licensee\u2019s plans for Commercialization activities for such Product and such country for the twelve (12) month period following the date of delivery of such Commercialization Plan. No Commercialization Plan may be implemented by Licensee if [***]. Each Commercialization Plan shall be consistent with and shall not contradict the terms of this Agreement [***], and in the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Notwithstanding the foregoing, if a [***], Licensee shall [***] and shall promptly [***].", "samples": [{"hash": "dKmUnICANcm", "uri": "/contracts/dKmUnICANcm#commercialization-plan", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.799451828, "published": true}, {"hash": "98Lw931j8Rs", "uri": "/contracts/98Lw931j8Rs#commercialization-plan", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.7310066223, "published": true}, {"hash": "fMKNF6r4YEI", "uri": "/contracts/fMKNF6r4YEI#commercialization-plan", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.591375351, "published": true}], "snippet_links": [{"key": "submission-of", "type": "clause", "offset": [37, 50]}, {"key": "regulatory-filings", "type": "clause", "offset": [51, 69]}, {"key": "provide-to", "type": "clause", "offset": [135, 145]}, {"key": "for-review", "type": "clause", "offset": [154, 164]}, {"key": "initial-commercialization-plan", "type": "clause", "offset": [169, 199]}, {"key": "in-the-territory", "type": "clause", "offset": [234, 250]}, {"key": "plans-for", "type": "clause", "offset": [313, 322]}, {"key": "details-of", "type": "clause", "offset": [431, 441]}, {"key": "by-licensee", "type": "clause", "offset": [470, 481]}, {"key": "specific-activities", "type": "clause", "offset": [497, 516]}, {"key": "applicable-to", "type": "clause", "offset": [526, 539]}, {"key": "certain-information", "type": "clause", "offset": [559, 578]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [605, 677]}, {"key": "confidential-treatment", "type": "definition", "offset": [679, 701]}, {"key": "with-respect-to", "type": "clause", "offset": [721, 736]}, {"key": "applicable-product", "type": "definition", "offset": [844, 862]}, {"key": "covered-by", "type": "definition", "offset": [886, 896]}, {"key": "time-periods", "type": "clause", "offset": [940, 952]}, {"key": "prior-to-the", "type": "clause", "offset": [958, 970]}, {"key": "first-commercial-sale", "type": "clause", "offset": [971, 992]}, {"key": "prior-to-launch", "type": "clause", "offset": [1303, 1318]}, {"key": "in-connection-with", "type": "clause", "offset": [1357, 1375]}, {"key": "sale-of", "type": "clause", "offset": [1449, 1456]}, {"key": "during-the-term", "type": "clause", "offset": [1470, 1485]}, {"key": "commercialization-plans", "type": "clause", "offset": [1539, 1562]}, {"key": "commercialization-activities", "type": "clause", "offset": [1700, 1728]}, {"key": "following-the", "type": "definition", "offset": [1796, 1809]}, {"key": "delivery-of", "type": "clause", "offset": [1818, 1829]}, {"key": "no-commercialization", "type": "clause", "offset": [1859, 1879]}, {"key": "consistent-with", "type": "definition", "offset": [1963, 1978]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [2008, 2031]}, {"key": "in-the-event-of", "type": "clause", "offset": [2043, 2058]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [2175, 2204]}, {"key": "licensee-shall", "type": "clause", "offset": [2218, 2232]}], "hash": "c3353de5016400a7d41cabad28fa3ca9", "id": 1}, {"size": 21, "snippet": "On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the \"Copromotion Territory Commercialization Plan\"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the \"Annual Commercialization Plan and Budget\"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.", "samples": [{"hash": "iM9xiHb4dzq", "uri": "/contracts/iM9xiHb4dzq#commercialization-plan", "label": "Collaboration and License Agreement (Viropharma Inc)", "score": 18.0, "published": true}, {"hash": "2I08g3szznK", "uri": "/contracts/2I08g3szznK#commercialization-plan", "label": "Collaboration and License Agreement (Viropharma Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "days-after", "type": "definition", "offset": [57, 67]}, {"key": "approval-of", "type": "definition", "offset": [119, 130]}, {"key": "territory-commercialization-plan", "type": "definition", "offset": [342, 374]}, {"key": "market-development", "type": "clause", "offset": [414, 432]}, {"key": "supply-and-distribution", "type": "clause", "offset": [452, 475]}, {"key": "each-calendar-year", "type": "definition", "offset": [623, 641]}, {"key": "commercialization-plan-and-budget", "type": "definition", "offset": [944, 977]}, {"key": "based-on", "type": "clause", "offset": [1042, 1050]}, {"key": "sales-efforts", "type": "clause", "offset": [1283, 1296]}, {"key": "development-plan-and-budget", "type": "definition", "offset": [1350, 1377]}, {"key": "first-full-calendar-year", "type": "definition", "offset": [1486, 1510]}, {"key": "the-annual", "type": "clause", "offset": [1524, 1534]}, {"key": "target-markets", "type": "clause", "offset": [1588, 1602]}, {"key": "distribution-channels", "type": "clause", "offset": [1607, 1628]}, {"key": "promotion-efforts", "type": "clause", "offset": [1668, 1685]}, {"key": "other-resources", "type": "clause", "offset": [1713, 1728]}, {"key": "by-each-party", "type": "clause", "offset": [1743, 1756]}, {"key": "performed-by", "type": "clause", "offset": [1818, 1830]}, {"key": "sales-forecasts", "type": "definition", "offset": [1865, 1880]}, {"key": "operating-expenses", "type": "clause", "offset": [1893, 1911]}, {"key": "the-product", "type": "definition", "offset": [1917, 1928]}, {"key": "expenses-and", "type": "clause", "offset": [2045, 2057]}, {"key": "regulatory-expenses", "type": "definition", "offset": [2085, 2104]}, {"key": "market-conditions", "type": "clause", "offset": [2285, 2302]}, {"key": "regulatory-issues", "type": "definition", "offset": [2304, 2321]}], "hash": "db97a9cea9f7b4de66f12f0a2eb40dc2", "id": 2}, {"size": 12, "snippet": "On a Collaboration Product-by-Collaboration Product basis, not later than [***] after commencement of the first Phase III Clinical Trial of a R&D Candidate in the Territory, ELAN shall prepare and the JSC shall review, and after due consideration by ELAN of any suggestions or comments, accept ELAN's rolling multi-year (being not less than[***]) plan for Commercializing the Collaboration Product in the Territory (the \"Commercialization Plan\"), which plan shall include without limitation [***]. The Commercialization Plan shall be updated by the ELAN at least once each calendar year. Not later than [***] after the filing of the first BLA for an R&D Candidate in the Territory and thereafter on or before August 31 of each calen dar year, ELAN shall prepare and the JSC shall review, and after due consideration by ELAN of any suggestions or comments, accept a long term plan (the \"Post BLA Filing Plan\"), which plan shall be based on and shall supersede the then current Commercialization Plan and which shall include [***]. The Post BLA Filing Budget shall be based on and shall supersede the relevant Commercialization Budget. The Post BLA Filing Plan will specify [***]. In preparing and updating the Commercialization Plan, Commercialization Budget, each Post BLA Filing Plan and each Post BLA Filing Budget, ELAN will take into consideration factors such as market conditions, regulatory issues and competition. If in any year of a Post BLA Filing Plan the aggregate expenses incurred by the Parties are in excess of [***] of the amounts set out in the Post BLA Filing Budget for that year (a \"Post BLA Excess Year\") then each Party shall charge to its R&D Account [***] of such [***] and, in addition, ELAN shall charge to its R&D Account any amounts in excess of such [***] (the \"Post BLA Excess Charge\"). All expenses incurred by the Parties in respect of any Post BLA Filing Budget and charged to their respective R&D Accounts shall be shared equally by the Parties in accordance with Section 5.3.1 and Section 5.3.4; provided, however, in any years following a Post BLA Excess Year CAT shall, in addition to any sums which may be due to ELAN under Section 5.3.4 for that year in respect of the then current Post BLA Filing Budget, pay to ELAN [***] of any Post BLA Excess Charges charged by ELAN to is R&D Account in each Post BLA Excess Year provided always that CAT's liability hereunder in any year shall not exceed [***] of [***] of the relevant Post BLA Filing Budget. If CAT's liability hereunder in any year does exceed [***] of [***] of the relevant Post BLA Filing Budget then this Section shall apply mutatis mutandis thereto.", "samples": [{"hash": "hudtALNFwmr", "uri": "/contracts/hudtALNFwmr#commercialization-plan", "label": "Research and Development (Cambridge Antibody Technology Group PLC)", "score": 18.0, "published": true}], "snippet_links": [{"key": "collaboration-product", "type": "definition", "offset": [5, 26]}, {"key": "commencement-of-the", "type": "clause", "offset": [86, 105]}, {"key": "phase-iii-clinical-trial", "type": "definition", "offset": [112, 136]}, {"key": "rd-candidate", "type": "definition", "offset": [142, 155]}, {"key": "in-the-territory", "type": "clause", "offset": [156, 172]}, {"key": "due-consideration", "type": "definition", "offset": [229, 246]}, {"key": "the-collaboration", "type": "clause", "offset": [372, 389]}, {"key": "without-limitation", "type": "clause", "offset": [472, 490]}, {"key": "each-calendar-year", "type": "definition", "offset": [568, 586]}, {"key": "long-term-plan", "type": "clause", "offset": [865, 879]}, {"key": "bla-filing", "type": "definition", "offset": [891, 901]}, {"key": "based-on", "type": "clause", "offset": [930, 938]}, {"key": "the-post", "type": "clause", "offset": [1030, 1038]}, {"key": "the-relevant", "type": "clause", "offset": [1095, 1107]}, {"key": "commercialization-budget", "type": "definition", "offset": [1108, 1132]}, {"key": "market-conditions", "type": "clause", "offset": [1368, 1385]}, {"key": "regulatory-issues", "type": "definition", "offset": [1387, 1404]}, {"key": "expenses-incurred", "type": "clause", "offset": [1477, 1494]}, {"key": "parties-are", "type": "clause", "offset": [1502, 1513]}, {"key": "set-out", "type": "definition", "offset": [1548, 1555]}, {"key": "each-party", "type": "definition", "offset": [1632, 1642]}, {"key": "in-respect-of", "type": "definition", "offset": [1855, 1868]}, {"key": "in-accordance-with", "type": "definition", "offset": [1980, 1998]}, {"key": "section-531", "type": "clause", "offset": [1999, 2012]}, {"key": "in-addition-to", "type": "clause", "offset": [2108, 2122]}, {"key": "pay-to", "type": "definition", "offset": [2246, 2252]}, {"key": "excess-charges", "type": "clause", "offset": [2280, 2294]}, {"key": "provided-always-that", "type": "clause", "offset": [2358, 2378]}], "hash": "7cdce4a56775e71cc068c9207be22ddc", "id": 3}, {"size": 6, "snippet": "In accordance with the Commercialization Plan (including the Launch Plan), Hutchmed (itself or through any other Hutchmed Entities) shall have the sole discretion and right to, and shall use Commercially Reasonable Efforts to, Commercialize (including booking sales, establishing pricing and related interactions with Governmental Authorities to be listed on the central or provincial reimbursement list, warehousing, commercial distribution, order processing, invoicing and collection) the Licensed Products in the Field in the Territory at its sole expense in each of (a) Mainland China, (b) Taiwan and (c) Hong Kong and Macau (it being understood that, if Hutchmed Commercializes Licensed Products in Hong Kong, it may be commercially reasonable to not separately also Commercialize Licensed Products in Macau). The Commercialization Plan will be developed on a [**] rolling basis and include the then-current [**] and the following [**]. At least [**] prior to anticipated approval of the first Drug Approval Application for a Licensed Product in the Field in the Territory, Hutchmed shall present the draft Commercialization Plan (including the Launch Plan) to the JCC for review, discussion and approval (so long as it is consistent with the terms and conditions of this Agreement and Hutchmed has taken into consideration in good faith the Global Brand Strategy). Notwithstanding the foregoing, if the first approval of the first Drug Approval Application for a Licensed Product in the Field in the Territory may be obtained such that is not possible for Hutchmed to present a draft Commercialization Plan [**] in advance, Hutchmed shall present such draft Commercialization Plan as soon as possible. Within [**] prior to the anticipated approval of the first Drug Approval Application for a Licensed Product in the Field in the Territory, Hutchmed shall submit to the JCC the final Commercialization Plan (including the Launch Plan) for review, discussion, and approval. Each [**] after the approval of the first Drug Approval Application for a Licensed Product in the Field in the Territory, Hutchmed shall submit to the JCC the Commercialization Plan for review, discussion, and approval. The Parties shall ensure at all times that the Commercialization Plan is consistent with the terms and conditions of this Agreement, and Hutchmed shall consider in good faith the Global Brand Strategy and the Global Medical Affairs Strategy.", "samples": [{"hash": "6D8V6PdkRqM", "uri": "/contracts/6D8V6PdkRqM#commercialization-plan", "label": "License Agreement (HUTCHMED (China) LTD)", "score": 33.1670074463, "published": true}, {"hash": "5eEfLY810ly", "uri": "/contracts/5eEfLY810ly#commercialization-plan", "label": "License Agreement (Epizyme, Inc.)", "score": 32.8548927307, "published": true}], "snippet_links": [{"key": "in-accordance-with", "type": "definition", "offset": [0, 18]}, {"key": "launch-plan", "type": "definition", "offset": [61, 72]}, {"key": "sole-discretion", "type": "definition", "offset": [147, 162]}, {"key": "right-to", "type": "definition", "offset": [167, 175]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [187, 222]}, {"key": "booking-sales", "type": "clause", "offset": [252, 265]}, {"key": "establishing-pricing", "type": "clause", "offset": [267, 287]}, {"key": "governmental-authorities", "type": "clause", "offset": [318, 342]}, {"key": "the-central", "type": "clause", "offset": [359, 370]}, {"key": "commercial-distribution", "type": "clause", "offset": [418, 441]}, {"key": "order-processing", "type": "definition", "offset": [443, 459]}, {"key": "licensed-products", "type": "definition", "offset": [491, 508]}, {"key": "in-the-field", "type": "clause", "offset": [509, 521]}, {"key": "in-the-territory", "type": "clause", "offset": [522, 538]}, {"key": "sole-expense", "type": "definition", "offset": [546, 558]}, {"key": "mainland-china", "type": "definition", "offset": [574, 588]}, {"key": "hong-kong", "type": "definition", "offset": [609, 618]}, {"key": "rolling-basis", "type": "definition", "offset": [870, 883]}, {"key": "approval-of", "type": "definition", "offset": [977, 988]}, {"key": "drug-approval-application", "type": "definition", "offset": [999, 1024]}, {"key": "for-review", "type": "clause", "offset": [1174, 1184]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [1248, 1286]}, {"key": "in-good-faith", "type": "definition", "offset": [1329, 1342]}, {"key": "global-brand-strategy", "type": "definition", "offset": [1347, 1368]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [1371, 1400]}, {"key": "first-approval", "type": "definition", "offset": [1409, 1423]}, {"key": "in-advance", "type": "clause", "offset": [1618, 1628]}, {"key": "as-soon-as-possible", "type": "definition", "offset": [1687, 1706]}, {"key": "prior-to-the", "type": "clause", "offset": [1720, 1732]}, {"key": "submit-to", "type": "definition", "offset": [1862, 1871]}, {"key": "the-final", "type": "clause", "offset": [1880, 1889]}, {"key": "the-approval", "type": "clause", "offset": [1995, 2007]}, {"key": "the-parties-shall", "type": "clause", "offset": [2199, 2216]}, {"key": "at-all-times", "type": "definition", "offset": [2224, 2236]}, {"key": "global-medical-affairs-strategy", "type": "definition", "offset": [2408, 2439]}], "hash": "bf0abb5caac40cf5ca7b7d8321385544", "id": 8}, {"size": 7, "snippet": "Licensee is a start-up venture having the strategic commitment to commercialize the Licensed Products and/or Licensed Processes in the Field of Use in the Territory, as appropriate, and Licensee has provided to the University a copy of its most recent Commercialization Plan;", "samples": [{"hash": "gN3klaEFeGP", "uri": "/contracts/gN3klaEFeGP#commercialization-plan", "label": "Control Algorithm License Agreement (Beta Bionics, Inc)", "score": 36.0143737793, "published": true}, {"hash": "8btWlRMUncM", "uri": "/contracts/8btWlRMUncM#commercialization-plan", "label": "Device License Agreement (Beta Bionics, Inc)", "score": 36.0143737793, "published": true}, {"hash": "SYfqQSyuTW", "uri": "/contracts/SYfqQSyuTW#commercialization-plan", "label": "Device License Agreement (Beta Bionics, Inc)", "score": 35.8993835449, "published": true}], "snippet_links": [{"key": "to-commercialize", "type": "definition", "offset": [63, 79]}, {"key": "licensed-products", "type": "definition", "offset": [84, 101]}, {"key": "licensed-processes", "type": "definition", "offset": [109, 127]}, {"key": "field-of-use", "type": "definition", "offset": [135, 147]}, {"key": "in-the-territory", "type": "clause", "offset": [148, 164]}, {"key": "to-the-university", "type": "clause", "offset": [208, 225]}, {"key": "a-copy-of", "type": "clause", "offset": [226, 235]}, {"key": "most-recent", "type": "definition", "offset": [240, 251]}], "hash": "27526ef84fea1e236099f5175d586e98", "id": 4}, {"size": 6, "snippet": "As soon as the information is available, but not later than [*] prior to the anticipated date of Commercialization for a Licensed Product, Celgene will prepare and provide to the JRC (for review but not approval) a summary of a plan that is a continuation of the Development Plan for such Licensed Product that summarizes the Commercialization activities for such Licensed Product (each, a \u201cCommercialization Plan\u201d). The Commercialization Plan shall include summary information related to marketing plans, publication planning, and launch plans and such other details agreed to by the Parties. Celgene will provide the JRC with annual updates and revisions to each Commercialization Plan and related budgets for the JRC\u2019s review but not approval.", "samples": [{"hash": "gi8NqCGkHFo", "uri": "/contracts/gi8NqCGkHFo#commercialization-plan", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.4544830322, "published": true}, {"hash": "9Uop5UAinMB", "uri": "/contracts/9Uop5UAinMB#commercialization-plan", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.421628952, "published": true}, {"hash": "6Dh96ZdWGv", "uri": "/contracts/6Dh96ZdWGv#commercialization-plan", "label": "Collaboration and Option Agreement (Globeimmune Inc)", "score": 24.3832988739, "published": true}], "snippet_links": [{"key": "the-information", "type": "clause", "offset": [11, 26]}, {"key": "prior-to-the", "type": "clause", "offset": [64, 76]}, {"key": "date-of", "type": "clause", "offset": [89, 96]}, {"key": "licensed-product", "type": "definition", "offset": [121, 137]}, {"key": "provide-to", "type": "clause", "offset": [164, 174]}, {"key": "the-jrc", "type": "clause", "offset": [175, 182]}, {"key": "for-review", "type": "clause", "offset": [184, 194]}, {"key": "the-development-plan", "type": "clause", "offset": [259, 279]}, {"key": "commercialization-activities", "type": "clause", "offset": [326, 354]}, {"key": "summary-information", "type": "clause", "offset": [458, 477]}, {"key": "related-to", "type": "clause", "offset": [478, 488]}, {"key": "marketing-plans", "type": "clause", "offset": [489, 504]}, {"key": "plans-and", "type": "definition", "offset": [539, 548]}, {"key": "other-details", "type": "clause", "offset": [554, 567]}, {"key": "by-the-parties", "type": "clause", "offset": [578, 592]}, {"key": "provide-the", "type": "clause", "offset": [607, 618]}, {"key": "updates-and-revisions", "type": "clause", "offset": [635, 656]}], "hash": "aad801ecfdcfbe5bac9e61f40c449473", "id": 7}, {"size": 5, "snippet": "Commercialization of Licensed Product under this Agreement shall be governed by a written Commercialization Plan that describes the anticipated commercialization activities (including promotional, marketing and sales activities) to be performed with respect to Licensed Product in the Territory by Licensee, its Affiliates, or it permitted Sublicensees, as well as projected timelines and annual budgets for such activities (the \u201cCommercialization Plan\u201d). The initial Commercialization Plan shall be drafted by Licensee no later than ***. On an annual basis thereafter (no later than *** of each Calendar Year), or more often as the Parties deem appropriate, the Licensee shall update and amend, as appropriate, the then-current Commercialization Plan. Such updates and amendments shall reflect any changes, re-prioritization of, or additions to the anticipated commercialization activities. Once provided to the JSC, each updated or amended Commercialization Plan shall become effective and supersede the previous Commercialization Plan as of the date of such provision or at such other time as decided by the JSC. In the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail.", "samples": [{"hash": "6Gc5pbklRed", "uri": "/contracts/6Gc5pbklRed#commercialization-plan", "label": "Development and License Agreement (Immunomedics Inc)", "score": 28.7125263214, "published": true}, {"hash": "75kHSbJOW1a", "uri": "/contracts/75kHSbJOW1a#commercialization-plan", "label": "Development and License Agreement (Immunomedics Inc)", "score": 28.7043113708, "published": true}, {"hash": "4VoQnjf7cYl", "uri": "/contracts/4VoQnjf7cYl#commercialization-plan", "label": "Development and License Agreement (Immunomedics Inc)", "score": 28.3538665771, "published": true}], "snippet_links": [{"key": "commercialization-of-licensed-product", "type": "clause", "offset": [0, 37]}, {"key": "commercialization-activities", "type": "clause", "offset": [144, 172]}, {"key": "marketing-and-sales-activities", "type": "clause", "offset": [197, 227]}, {"key": "with-respect-to", "type": "clause", "offset": [245, 260]}, {"key": "in-the-territory", "type": "clause", "offset": [278, 294]}, {"key": "by-licensee", "type": "clause", "offset": [295, 306]}, {"key": "permitted-sublicensees", "type": "clause", "offset": [330, 352]}, {"key": "annual-budgets", "type": "definition", "offset": [389, 403]}, {"key": "initial-commercialization-plan", "type": "clause", "offset": [460, 490]}, {"key": "drafted-by", "type": "clause", "offset": [500, 510]}, {"key": "annual-basis", "type": "definition", "offset": [545, 557]}, {"key": "each-calendar-year", "type": "definition", "offset": [591, 609]}, {"key": "the-parties", "type": "definition", "offset": [629, 640]}, {"key": "the-licensee-shall", "type": "clause", "offset": [659, 677]}, {"key": "updates-and-amendments", "type": "clause", "offset": [758, 780]}, {"key": "become-effective", "type": "clause", "offset": [971, 987]}, {"key": "date-of", "type": "clause", "offset": [1048, 1055]}, {"key": "other-time", "type": "clause", "offset": [1082, 1092]}, {"key": "in-the-event-of", "type": "clause", "offset": [1116, 1131]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [1209, 1232]}], "hash": "abef71b3fbcb6b9b877f27aad079a7f1", "id": 10}, {"size": 7, "snippet": "Prior to signing this AGREEMENT, LICENSEE has provided to UNIVERSITY a written plan (hereinafter \u201cCOMMERCIALIZATION PLAN\u201d) for the LICENSED PRODUCT within the respective LICENSED FIELD and within the respective country or countries of the LICENSED TERRITORY to be introduced by LICENSEE into commercial use. The COMMERCIALIZATION PLAN shall include, without limitation: (1) planned research and development activities, (2) milestones and evidence of sufficient financial resources to successfully implement the COMMERCIALIZATION PLAN and ensure that LICENSED PRODUCT will be kept reasonably available to the public, and (3) projection of sales and proposed marketing efforts. Such COMMERCIALIZATION PLAN is incorporated as Appendix B.", "samples": [{"hash": "jBl49AMv3s5", "uri": "/contracts/jBl49AMv3s5#commercialization-plan", "label": "License Agreement (Solid Biosciences Inc.)", "score": 35.1957550049, "published": true}, {"hash": "dgb4yTdtd0V", "uri": "/contracts/dgb4yTdtd0V#commercialization-plan", "label": "License Agreement (Solid Biosciences, LLC)", "score": 29.0410671234, "published": true}, {"hash": "6L0J5UBrAmN", "uri": "/contracts/6L0J5UBrAmN#commercialization-plan", "label": "License Agreement (Solid Biosciences, LLC)", "score": 28.9917869568, "published": true}], "snippet_links": [{"key": "prior-to", "type": "definition", "offset": [0, 8]}, {"key": "this-agreement", "type": "clause", "offset": [17, 31]}, {"key": "to-university", "type": "clause", "offset": [55, 68]}, {"key": "written-plan", "type": "definition", "offset": [71, 83]}, {"key": "licensed-product", "type": "definition", "offset": [131, 147]}, {"key": "licensed-field", "type": "definition", "offset": [170, 184]}, {"key": "licensed-territory", "type": "definition", "offset": [239, 257]}, {"key": "by-licensee", "type": "clause", "offset": [275, 286]}, {"key": "commercial-use", "type": "definition", "offset": [292, 306]}, {"key": "without-limitation", "type": "clause", "offset": [350, 368]}, {"key": "research-and-development-activities", "type": "clause", "offset": [382, 417]}, {"key": "evidence-of", "type": "definition", "offset": [438, 449]}, {"key": "sufficient-financial-resources", "type": "clause", "offset": [450, 480]}, {"key": "available-to-the-public", "type": "definition", "offset": [591, 614]}, {"key": "marketing-efforts", "type": "definition", "offset": [657, 674]}], "hash": "65819bf07fc6b332cff82edd88a0debb", "id": 5}, {"size": 7, "snippet": "(a) No later than [ * ] prior to the anticipated filing of an application for Regulatory Approval for a Product in the U.S., Endo shall deliver to the JSC a draft written commercialization plan setting forth anticipated material commercialization activities to be performed with respect to such Product in the U.S. by Endo or on its behalf, as well as projected timelines for such activities (the \u201cCommercialization Plan\u201d). The JSC shall promptly review such draft initial Commercialization Plan and may provide commercially reasonable comments to Endo for its consideration. Endo shall give good faith consideration to such comments and may revise such draft Commercialization Plan to implement such of the JSC\u2019s comments that it shall deem necessary or advisable to include in the draft. Endo shall, thereafter, submit the Commercialization Plan with such changes, revisions and modifications that it shall deem advisable to the JSC, and the Commercialization Plan, together with such changes, revisions and modifications, as applicable, shall be deemed final.\n(b) No later than [ * ] prior to the anticipated launch of a Product in the U.S., Endo shall update the Commercialization Plan, and shall thereafter update the Commercialization Plan on an annual basis as follows: Endo shall provide the JSC with a draft update to the Commercialization Plan no later than December 1 of each year. Endo shall give good faith consideration to any comments provided by the JSC and may revise such Commercialization Plan to implement such of the JSC\u2019s comments that it shall deem necessary or advisable to include in the Commercialization Plan, after which the update to the Commercialization Plan shall be deemed to be finalized. Endo shall deliver a final version of the updated Commercialization Plan no later than January 31 of the following year.\n(c) The Commercialization Plan shall include a marketing plan for the Product for which Regulatory Approval is being sought or obtained in the U.S. that includes plans related to the anticipated promotion and sale of such Product in the U.S., competitive analysis, including information regarding actions intended to mitigate competitive threats, a non-binding sales forecast for the following year and the marketing, promotion and advertising campaigns proposed to be conducted, including the number of detailing representatives, level of promotion and Endo\u2019s medical education activities.", "samples": [{"hash": "95LTkxfurhx", "uri": "/contracts/95LTkxfurhx#commercialization-plan", "label": "License, Development and Supply Agreement (Alexza Pharmaceuticals Inc.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "prior-to-the", "type": "clause", "offset": [24, 36]}, {"key": "application-for-regulatory-approval", "type": "clause", "offset": [62, 97]}, {"key": "the-us", "type": "clause", "offset": [115, 122]}, {"key": "deliver-to", "type": "definition", "offset": [136, 146]}, {"key": "activities-to-be-performed", "type": "clause", "offset": [247, 273]}, {"key": "with-respect-to", "type": "clause", "offset": [274, 289]}, {"key": "by-endo", "type": "clause", "offset": [315, 322]}, {"key": "initial-commercialization-plan", "type": "clause", "offset": [465, 495]}, {"key": "commercially-reasonable", "type": "clause", "offset": [512, 535]}, {"key": "good-faith-consideration", "type": "clause", "offset": [592, 616]}, {"key": "revisions-and-modifications", "type": "clause", "offset": [867, 894]}, {"key": "annual-basis", "type": "definition", "offset": [1252, 1264]}, {"key": "provide-the", "type": "clause", "offset": [1288, 1299]}, {"key": "plan-no", "type": "clause", "offset": [1349, 1356]}, {"key": "each-year", "type": "definition", "offset": [1382, 1391]}, {"key": "final-version", "type": "definition", "offset": [1744, 1757]}, {"key": "following-year", "type": "definition", "offset": [1828, 1842]}, {"key": "marketing-plan", "type": "clause", "offset": [1891, 1905]}, {"key": "the-product", "type": "definition", "offset": [1910, 1921]}, {"key": "related-to", "type": "clause", "offset": [2012, 2022]}, {"key": "sale-of", "type": "clause", "offset": [2053, 2060]}, {"key": "competitive-analysis", "type": "clause", "offset": [2087, 2107]}, {"key": "information-regarding", "type": "clause", "offset": [2119, 2140]}, {"key": "to-mitigate", "type": "definition", "offset": [2158, 2169]}, {"key": "a-non", "type": "clause", "offset": [2191, 2196]}, {"key": "sales-forecast", "type": "definition", "offset": [2205, 2219]}, {"key": "advertising-campaigns", "type": "definition", "offset": [2276, 2297]}, {"key": "number-of", "type": "definition", "offset": [2338, 2347]}, {"key": "medical-education-activities", "type": "definition", "offset": [2405, 2433]}], "hash": "a861a27bdfc2fff400c0eb0eb9f843d6", "id": 6}, {"size": 5, "snippet": "The Parties shall annually update their part of the Commercialization Plan for the following Calendar Year before a mutually agreeable date prior to December 31 in the preceding year. The JCC shall consider and discuss the revised plans, and ARIAD SWISSCO shall consider in good faith the input of ARIAD US on the ARIAD SWISSCO part of the Commercialization Plan for the Territory. ARIAD SWISSCO shall use Commercially Reasonable Efforts to implement its part of the then current Commercialization Plan.", "samples": [{"hash": "dBkrm21SobK", "uri": "/contracts/dBkrm21SobK#commercialization-plan", "label": "Buy in License Agreement", "score": 31.3408622742, "published": true}, {"hash": "iFdBVtByHQc", "uri": "/contracts/iFdBVtByHQc#commercialization-plan", "label": "Buy in License Agreement (Ariad Pharmaceuticals Inc)", "score": 28.1184120178, "published": true}, {"hash": "2PmEljVFp2Z", "uri": "/contracts/2PmEljVFp2Z#commercialization-plan", "label": "Buy in License Agreement (Incyte Corp)", "score": 27.6036968231, "published": true}], "snippet_links": [{"key": "the-parties-shall", "type": "clause", "offset": [0, 17]}, {"key": "calendar-year", "type": "definition", "offset": [93, 106]}, {"key": "prior-to-december", "type": "clause", "offset": [140, 157]}, {"key": "preceding-year", "type": "definition", "offset": [168, 182]}, {"key": "revised-plans", "type": "clause", "offset": [223, 236]}, {"key": "ariad-swissco", "type": "clause", "offset": [242, 255]}, {"key": "in-good-faith", "type": "definition", "offset": [271, 284]}, {"key": "ariad-us", "type": "definition", "offset": [298, 306]}, {"key": "the-territory", "type": "clause", "offset": [367, 380]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [402, 437]}], "hash": "e5d9cc1fbf852eef4b76cc78ab70c29b", "id": 9}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ih9jb21tZXJjaWFsaXphdGlvbi1wbGFuIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"parents": [["commercialization", "Commercialization"], ["definitions", "Definitions"], ["development", "Development"], ["development-and-commercialization", "Development and Commercialization"], ["additional-definitions", "Additional Definitions"]], "size": 575, "children": [["initial-commercialization-plan", "Initial Commercialization Plan"], ["general", "General"], ["contents-of-commercialization-plan", "Contents of Commercialization Plan"], ["initial-plan-and-amendments", "Initial Plan and Amendments"], ["updates-to-commercialization-plan", "Updates to Commercialization Plan"]], "title": "Commercialization Plan", "id": "commercialization-plan", "related": [["development-plan", "Development Plan", "Development Plan"], ["development-plans", "Development Plans", "Development Plans"], ["development-and-commercialization", "Development and Commercialization", "Development and Commercialization"], ["commercialization", "Commercialization", "Commercialization"], ["marketing-plan", "Marketing Plan", "Marketing Plan"]], "related_snippets": [], "updated": "2026-07-08T06:29:01+00:00", "also_ask": ["What are the minimum requirements for a robust and enforceable commercialization plan?", "How can parties negotiate flexibility versus specificity in the plan\u2019s milestones and deliverables?", "What are the key risks if the plan lacks clear performance metrics or timelines?", "How do courts assess material breaches or failures to execute the commercialization plan?", "How does this clause compare to industry standards or similar agreements in your jurisdiction?"], "drafting_tip": "Specify required plan elements to ensure clarity, set deadlines for submission to promote timely action, and define approval criteria to prevent disputes.", "explanation": "A Commercialization Plan clause outlines the strategy and steps that parties will follow to bring a product, service, or intellectual property to market. It typically details responsibilities, timelines, milestones, and resource commitments required for successful commercialization, and may specify performance metrics or reporting obligations. This clause ensures that all parties are aligned on the process and expectations for turning an innovation or asset into a marketable offering, thereby reducing misunderstandings and increasing the likelihood of commercial success."}, "json": true, "cursor": ""}}